Madrigal Phase III Success In NASH Spurs Buyout Speculation

 
• By Joseph Haas

With resmetirom hitting its co-primary endpoints, Madrigal intends to file the THRβ agonist for approval during H1 2023 in the liver disease, an unmet medical need with blockbuster earnings potential.

Speculation
Will Madrigal's Phase III NASH data lead to buyout offers? • Source: Shutterstock

More from Clinical Trials

More from R&D